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A Ab bs st tr ra ac ct t
There have been significant advances in our knowledge about the molecular changes that precede and
accompany the development of inherited predispositions to colorectal cancer. In this review the clinical relationship
to the molecular changes associated with the polyposis syndromes is presented. The aim is to put into context
the diverse findings that have been shown to be associated with the development of colorectal cancer in persons
who harbor a predisposition to develop disease at unusually early ages. The main focus will be on familial
adenomatous polyposis as it serves as a model disease and is the most extensively studied of all of the polyposis
syndromes. In addition some information is provided that explains the relationship between a germline change
in one gene and what consequences that can have for a particular cell and the development of disease.
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I In nt tr ro od du uc ct ti io on n   
Since the advent of human genome project there
has been a revolution not only in our understanding of
cellular function but also with respect to how we view
all types of disease, from psychiatric illness, coronary
heart disease, neurological disorders, to cancer. No
longer can we assume that pathological changes can
be diagnosed in terms of descriptive differences between
normal and diseased tissue. Recent molecular biological
developments are now providing better and earlier
disease definition than previously thought possible. This
trend will continue such that accurate diagnosis of
disease will be easier to perform and consequently more
specific  treatment  strategies  applied.  With  the
identification of genes associated with disease more
knowledge is also gained by a better understanding of
the cellular events that cause overt illness.
For the first time in the history of medicine we are
now able to predict in certain groups of patients (with
a very high degree of accuracy), who is more likely to
become ill. Unfortunately, society may not be prepared
for such a radical change as ongoing discussions
concerning the benefits of presymptomatic diagnosis
continue to dominate the introduction of these new
methodologies. Nevertheless, this trend in preventative
medicine will continue and grow as it offers for the
patient the best prognosis should they be identified as
being at risk of developing the disease. 
With respect to cancer, significant advances have
been made in our understanding of how it develops and
slowly the molecular changes that precede overt disease
are being unravelled. It is now considered a multifaceted
disease, which involves diverse mechanisms such as
DNA repair, cell signalling and apoptosis, all of which
contribute to the development of the malignant cell. With
respect to this review, all of these mechanisms can be
shown to contribute to colorectal cancer in persons who
carry a genetic predisposition.
G Ge en ne et ti ic cs s   o of f   t th he e   P Po ol ly yp po os si is s   S Sy yn nd dr ro om me es s
There  is  abundant  clinical  and  pathological
evidence,  which  suggests  that  colorectal  cancer
develops in a sequential manner through a series of
events that can be followed during the progression of
the disease from early adenoma through to metastatic
disease. The molecular events that are associated withH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2003; 1(1) 20
Rodney J. Scott
initiation and progression of the disease are gradually
being dissected. As the molecular characterization of
colorectal  cancer  continues  new  mechanisms  of
initiation and progression are becoming evident. In this
review a description of the current knowledge of
polyposis development shall be presented with a special
emphasis on familial adenomatous polyposis (FAP). 
Colorectal cancer is the second most common
malignancy in Europe and North America with similar
incidence  rates  for  both  men  and  women.
Epidemiological studies suggest that environmental
factors play a significant role in the etiology of disease
[1]. For example the incidence of colorectal cancer
(CRC) is very much higher in countries where the diet is
rich in fat and low in fibre [2, 3]. Furthermore, there exist
a number of distinct genetic syndromes, which predispose
persons to the development of CRC, some of which are
listed in Table 1. From this table there are two genetic
entities  (Familial  Adenomatous  Polyposis  Coli  and
Hereditary Non-Polyposis Colorectal Cancer) which
predispose  persons  to  an  extremely  high  risk  of
developing CRC at a young age. In addition to CRC,
other malignancies and symptoms tend to aggregate in
these families implying that the affects of the predisposition
are not restricted to the colon alone. Interestingly, not all
signs of disease are necessarily malignant nor are they
always readily apparent, a good example being the
presence of osteomas and supernumerary teeth in FAP .
An often-overlooked aspect of any hereditary disease is
that persons carrying a genetic predisposition do not
initially have CRC but they have the susceptibility to
develop  it.  This  implies  that  other  genetic  and
environmental factors can and do influence disease
expression. Therefore, it must always be borne in mind
that there are essentially two factors that influence the
expression of disease, one being genetic and the other
environmental. As a general rule, genetic influences occur
early in life whereas only later do environmental effects
become more apparent (as is the case for colorectal
cancer occurring in persons who have no apparent
genetic predisposition to disease). However, both effects
interact with one another such that genetic factors may
be minimised by avoiding certain environmental risks or
by actively seeking preventative agents. The trigger that
initiates the development of CRC is not known but it is
believed that the colonic environment plays a crucial
role. Recent epidemiological studies have revealed for
instance that moderate dose aspirin has a protective
affect with respect to CRC incidence in the general
population  [4-6].  When  considering  genetic
predispositions to CRC similar environmental influences
can inhibit the development of disease as is the case with
nonsteroidal anti-inflammatory drugs, which include such
agents as aspirin and Sulindac [7]. Thus CRC is not in
itself inherited but the susceptibility, which favours its
development, is.
Since genetic predispositions to colorectal cancer
provide  a  unique  insight  into  the  cellular  and
biochemical  changes  that  occur  during  disease
development, many studies have been performed to
investigate the earliest genetic changes that occur
during the transition from normal cellular growth to
neoplasia in familial cancer and compare them to
those occurring in sporadic disease. 
T Th he e   G Ge en ne et ti ic c   M Mo od de el l   o of f   C CR RC C
The  development  of  CRC  from  normal  tissue
through hyperplasia, adenomas, pre-invasive, invasive
and finally metastatic disease is much more apparent
than in any other common malignancy such as breast
or lung cancer. The molecular genetics of CRC are
probably  the  best  understood  of  the  common
malignancies,  as  it  is  relatively  easy  to  obtain
premalignant and malignant tissue at various stages
of neoplastic development. This and the fact that there
exist familial forms of CRC has allowed for detailed
molecular investigations to be performed. For the
remainder of this review a description of the molecular
genetic events that appear to underlie the development
of the adenomatous polyposis syndromes shall be
presented  as  well  as  some  information  on  the
development of hamartomatous polyposis. 
One of the most significant findings concerning
CRC was the discovery not only in sporadic CRC but
also in FAP that it appeared to arise from the clonal
expansion of a subset of cells that had acquired a
particular growth advantage after a somatic mutation
[8]. Additional support for the clonal expansion of cells
in human CRC came from parallel studies in mice,
which were fed dietary carcinogens and subsequently
developed CRC [9]. Such findings are in direct contrast
to normal mucosa, which is polyclonal even in the
normal mucosa of patients with FAP [10]. Taken
together these results imply that a somatic mutational
event is necessary before adenoma development can
proceed. This is of particular relevance with respect to
inherited  forms  of  CRC  as  they  too  require  an
additional somatic mutational event before adenoma
development  implying  a  “second  hit“,  which  is
consistent with Knudsons’ “Two Hit“ hypothesis [11].
The “two-hit” theory implies that the initiation of cancer
is not a single process and that two independent events
should occur before disease becomes overt. The two
hit model has been extensively modified since the
discovery of tumor suppresser genes as the original
hypothesis implied that the second hit was at an entirely
different site to that of the first [12]. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2003; 1(1) 21
Familial Adenomatous Polyposis (FAP) and Other Polyposis Syndromes
F Fa am mi il li ia al l   A Ad de en no om ma at to ou us s   P Po ol ly yp po os si is s
Over recent years significant advances have been
made in our understanding of the molecular genetic
events associated with CRC due to intensive investigations
into FAP . This is an autosomal dominantly inherited
disease that accounts for approximately 1% of all CRC
cases observed and has a prevalence of approximately
1 in 10,000 [13, 14]. Phenotypically, FAP is characterised
by the presence of hundreds to thousands of small
adenomatous polyps, which if left untreated would almost
certainly develop into colorectal cancer. Characteristically,
FAP has a very high penetrance with virtually all gene
carriers presenting with colonic polyposis by their fourth
decade and without intervention succumbing to it by the
middle of their fifth decade of life. The site of colonic
adenoma development is not restricted to particular parts
of the colon, however, there is a tendency for colorectal
cancer  to  develop  distally.  Heterogeneity  does,
nevertheless, exist such that milder and more severe forms
of the disease (referred to as Attenuated Adenomatous
Polyposis Coli, AAPC and the Flat Adenoma Syndrome
or FAS) have been described which can make for a
difficult clinical diagnosis [15-17]. Lower polyp number,
later age of onset and slower disease progression
distinguishes AAPC whereas FAS presents with multiple
flat  adenomas  throughout  the  colon  and  is  also
associated  with  slower  disease  development  and
progression and later average age of onset. 
In addition to colonic symptoms, there occur other
extra-colonic  manifestations,  which  appear  to  be
associated with FAP as shown in Table 2. The association
of osteomas, epidermoid cysts and polyposis continues
to be referred to as Gardner’s syndrome as it was first
described by Eldon Gardner over 50 years ago [18]. Most
FAP patients who have been treated for their colonic
disease tend to succumb to extra-colonic disease rather
T Ta ab bl le e   1 1. .   I In nh he er ri it te ed d   P Pr re ed di is sp po os si it ti io on ns s   t to o   C Co ol lo or re ec ct ta al l   C Ca an nc ce er r
S Sy yn nd dr ro om me es s   w wi it th h   p pr re ee ex xi is st ti in ng g   p po ol ly yp po os si is s
D Di is se ea as se e G Ge en ne e D Di is se ea as se e   P Ph he en no ot ty yp pe e
Familial Adenomatous Polyposis APC colonic polyposis 
Gardner’s Syndrome APC colonic polyposis in association with extra colonic lesions
Oldfield’s Syndrome APC colonic polyposis in association with sebaceous cysts
Turcot’s Syndrome* APC malignant tumors of the central nervous system 
in association with polyposis of the colon
S Sy yn nd dr ro om me es s   w wi it th h   p pr re ee ex xi is st ti in ng g   h ha am ma ar rt to om ma at to ou us s   p po ol ly yp ps s
Peutz-Jeghers syndrome LKB1/STK11 abnormal pigmentation on the lips and buccal mucosa
Ruvalcaba-Myhre-Smith syndrome Unknown macrocephaly, pigmented macules on the penis
(Bannayan-Riley-Ruvalcaba Syndrome)
Juvenile polyposis SMAD4 (DPC) cystic hamartomatous polyps
Cowden’s syndrome PTENmultiple hamartomatous lesions, primarily on the 
mucocutaneous tissue)
S Sy yn nd dr ro om me es s   w wi it th ho ou ut t   p pr re ee ex xi is st ti in ng g   p po ol ly yp po os si is s
Hereditary non-polyposis colorectal cancer hMSH2 few if any polyps, CRC tends to be site specific
(Lynch Type I and Type II syndromes) hMLH1
hPMS1
hPMS2
hMSH6
Muir-Torre’s Syndrome# hMSH2 Lynch type II syndrome with dermatological 
lesions and laryngeal cancer
Turcot’s Syndrome* hMSH2 Glioblastoma Multiforme Astrocytoma grades 3 or 4
hMLH1
*Turco’ts Syndrome is a special case, see below. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2003; 1(1) 22
than colorectal cancer [19]. Today, CRC development
can be prevented by prophylactic removal of the colon.
As a consequence of surgical intervention patients live
longer but now are faced with the prospect of developing
other manifestations of the disease which are much more
resistant to treatment. Examples of which include desmoid
disease and upper gastrointestinal adenocarcinomas,
which  often  do  not  respond  to  current  treatment
approaches. A full understanding of the mechanisms that
underlie the development of extra-colonic disease in FAP
could provide some insight towards a better rationale of
treatment as current methods appear to be ineffective
especially when considering desmoid disease. Not all
manifestations of the disease are necessarily malignant
and indeed some of them may be useful in identifying
asymptomatic persons who could be at risk of developing
CRC. An example of such a symptom is shown in Table
2, it being congenital hypertrophy of the retinal pigment
epithelium (or CHRPE) that was first described in 1980
[20], which is a feature of both Gardner’s syndrome and
FAP. CHRPEs can be identified ophthalmologically and
can occur as single or multiple lesions on the retina,
which do not lead to any major disturbances in vision.
The symptom of CHRPEs is interesting as it segregates
with polyposis in some families. Initially, it was believed
that this manifestation of the disease could be used as a
non-invasive marker for determining the carrier status of
non-symptomatic persons within any given family [21].
It became evident that this symptom could not be relied
upon for an accurate diagnosis as not all FAP patients
even within the same family may necessarily present with
this sign. It remains useful, however, in those families
where segregation of this trait can be linked to CRC
development.
S Sy yn nd dr ro om me es s   A As ss so oc ci ia at te ed d   w wi it th h   F Fa am mi il li ia al l   
A Ad de en no om ma at to ou us s   P Po ol ly yp po os si is s
O Ol ld df fi ie el ld d’ ’s s  S Sy yn nd dr ro om me e
Oldfield’s syndrome is similar to polyposis except
for the additional symptom of multiple sebaceous cysts
[22]. It is not clear if this is a chance association or a
true extra-colonic manifestation of FAP , however, it is
of note that it is quite a common feature in some
mouse models of the disease (R. Fodde, personal
communication). This syndrome is extremely rare. 
T Tu ur rc co ot t’ ’s s  S Sy yn nd dr ro om me e
Turcot first described the association of colorectal
polyposis and brain tumors in 1959 where two teenage
siblings were described with polyposis of the colon and
malignancies of the central nervous system. One of
the patients was diagnosed with a medulloblastoma
involving the spinal cord and the other a cerebral
glioblastoma multiforme and a pituitary tumor [23].
Since this first observation more than 120 cases have
been reported with differing degrees of colonic disease
severity,  some  cases  only  presenting  with  one
adenomatous polyp and others with typical polyposis.
Recently, a molecular basis for Turcot’s syndrome has
been proposed based on the finding that two inherited
colorectal cancer predispositions are involved, namely
FAP and hereditary nonpolyposis colorectal cancer
(HNPCC). Turcot’s syndrome associated with FAP
appears to be somewhat specific with respect to the
development  of  central  nervous  system  tumors.
Medulloblastomas appear to be the prominent brain
lesion in persons harboring APC germline mutations,
however, anaplastic astrocytomas and ependymomas
have been reported [24]. Little is known about the
molecular events that give rise to brain tumors in FAP
or HNPCC.
F Fa am mi il li ia al l  I In nf fi il lt tr ra at ti iv ve e  F Fi ib br ro om ma at to os si is s  ( (F FI IF F) )
For many years FIF (more commonly known as
desmoid disease) was considered a separate entity to
FAP .  In  1996  one  report  was  published  linking
mutations in the APC gene to FIF [25]. A second report
was published by another group, which confirmed the
notion that some APC gene mutations resulted in a
much greater predisposition to desmoid disease than
others [26]. The mutation site in the APC gene, which
correlated with desmoid disease was identified as lying
towards the 3’ end of the gene. Of the four families
Scott et al. [25] investigated 3 which were found to
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T Ta ab bl le e   2 2. .   Symptoms observed in FAP 
S Sy ym mp pt to om ms s   o ob bs se er rv ve ed d   i in n   F FA AP P
Polyposis
Hepatoblastoma
Desmoids
Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE)
Periampullary carcinomas
Osteomas
Epidermoid Cysts
Small Intestinal carcinomas
Gastric Polyps
Dental AbnormalitiesH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2003; 1(1) 23
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harbor an identical mutation and were also discovered
by haplotype analysis to be related to on another. The
fourth family did not appear to harbor any germline
mutation in the APC gene, suggestive of a second gene
associated with this disorder. In the initial reports,
colonic disease was not described as a feature, but
subsequent to the report by Eccles et al. [26] micro-
adenomas were identified indicating a mild colonic
phenotype suggestive of an increased risk of colorectal
cancer (K. Nugent, personal communication).
S Se ea ar rc ch hi in ng g   f fo or r   t th he e   A AP PC C   G Ge en ne e   a an nd d   i it ts s   F Fu un nc ct ti io on n
The  first  advance  in  the  understanding  of  the
molecular nature of FAP occurred after the discovery by
Herrera et al. [27] of a mentally retarded male who
presented with Gardner’s syndrome. Cytogenetic analysis
revealed that the patient had an interstitial deletion of the
long arm of chromosome 5q. Within 5 years of Herrera’s
discovery the gene responsible for FAP was identified
simultaneously by two groups and is now commonly
known as the Adenomatous Polyposis Coli (APC) gene
[28-31]. The APC gene contains an 8538 bp open
reading frame and consists of 18 exons [32]. The first
three exons are not transcribed and the next 14 are
relatively short with the eighteenth being one of the largest
exons so far described for any gene, spanning over three
quarters of the entire coding sequence (6577 bp) of the
gene. When the gene was initially reported only fifteen
exons were described (14 small exons and 1 large exon),
after which most researchers describe the gene as being
composed  of  15  exons  [29].  There  exist  several
differentially spliced versions of the APC gene, one splice
variant is associated with exon 9 and this may be linked
to the milder disease phenotype that FAP patients present
with when they harbor mutations in this exon [33]. 
In colonic epithelium the APC gene appears to be
present in two different forms, which gives rise to two
mRNA transcripts, one being approximately 300 bases
longer than the other with the largest being the most
abundant [29, 34]. In contrast, in the oesophagus,
there is only a relatively short transcript present, which
may provide a clue as to why this site appears to be
spared from polyp development [32]. 
Localization of the full length APC protein indicates
that it is neither nuclear or membrane bound and that it
appears in the non-soluble fraction of the cell. Truncated
forms of the protein appear both in the soluble and
insoluble fractions of the cell, implying that they may be
oligomerizing with the full-length protein [28, 30]. The
N-terminal  region  is  responsible  for  APC  homo-
dimerization, and most mutant APC molecules retain the
capacity to dimerize with wild type APC both in vivo and
in vitro [35, 36]. The second significant feature of the
APC gene product is its interaction with the adherins
junction proteins called catenins, to date at least three
proteins have been identified that interact with APC, these
being α-catenin, β-catenin and plakoglobin (a γ-like
catenin) which all bind to E-cadhedrin [37]. Some of the
repeat amino acid sequences in the central region of the
APC protein are postulated to be responsible for this
interaction [35, 38]. Evidence suggests that catenins are
involved in the transmission of adhesion signals and in
the  anchorage  of  adherins  junctions  to  the  actin
cytoskeleton [39]. Furthermore, the APC protein has been
shown to associate with microtubules as shown by its
binding to tubulin in vitro leading to the promotion of
microtubule assembly [40, 41]. Mutated forms of the APC
gene that lack the carboxy terminus of the protein failed
to elicit similar responses providing some evidence in
favour of microtubule binding. 
Together, information concerning the structure and
molecular association of the APC protein indicate that
it is associated with the cytoskeleton and in regulation
of contact inhibition [42]. APC has been shown to bind
to β-catenin, suggesting a role in mediating extra-
cellular communication from cadherin to the nucleus.
Importantly, too much β-catenin in the nucleus will result
in apoptosis, which would tend towards a decreased
incidence of tumor formation therefore closer attention
needs to be focused on the role of mutant APC alleles
and how they modulate cellular control (see below).
Other proteins are also implicated in the formation and
regulation of the APC-catenin complex. Regulation of
APC-β-catenin  complex  assembly  appears  to  be
mediated by a protein similar to GSK3β (glycogen
synthase kinase 3β) which binds directly to the complex
[43]. Other proteins have also been identified that also
bind to particular amino acid sequences, most notably
the Drosophila Discs large tumor suppresser protein
(DLG), which is believed to play a role in regulating cell
cycle progression and neuronal function [44].
C Co ol lo or re ec ct ta al l   C Ca an nc ce er r   D De ev ve el lo op pm me en nt t   
a an nd d   t th he e   A AP PC C   G Ge en ne e
Evidence  that  the  APC  gene  is  involved  in  the
development of colorectal cancer can be summarised as
follows: deletions of chromosome 5q result in the APC
phenotype. Persons harboring an APC germline mutation
invariably develop colorectal cancer, which is usually
preceded  by  a  florid  polyposis.  Restoration  of
chromosome 5 by microcell mediated chromosome
transfer results in a reversion of a tumor phenotype in
colorectal cancer cell lines thus indicating that a gene orH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2003; 1(1) 24
set of genes on this chromosome can suppress colonic
tumor development [45, 46]. Introduction of the APC
gene to colon cancer cell lines causes a reversion in
tumor phenotype [47]. Together this evidence indicates
strongly that the APC gene is a tumor suppresser gene
and is directly involved in colorectal cancer development. 
Phenotypic variation between patients with different
mutations in the APC gene can be explained by the “Just-
Right“ signalling model proposed by Albuquerque et al.
[48]. In this model it is proposed that partially functional
alleles of APC are sufficient to poorly regulate the levels
of β-catenin. Sufficient accumulation of β-catenin occurs
within the nucleus to activate certain key transcription
factors that promote tumor development but insufficient
levels are reached to trigger apoptosis. The model is
based on findings, which show that different sites of
mutation in the APC gene influence the type of second
hit on the wild type allele prior to tumor formation.
Germline mutations that occur between codons 1,194
and 1,392 appear to be almost exclusively associated
with somatic loss of the wild type allele in contrast to
other germline mutations, located outside of this region,
which appear to be linked to somatic mutations in the
wild type APC allele [49]. 
An alternative explanation for the mild phenotype
observed in patients harboring mutations 5’ of codon
157 is the presence of a second initiation codon at a
position upstream of codon 157 which could remove
any problems associated with mutations within the 5’
region of the gene [50]. 
O Ot th he er r   G Ge en ne es s   
A As ss so oc ci ia at te ed d   w wi it th h   C Co ol lo or re ec ct ta al l   C Ca an nc ce er r   
i in n   F Fa am mi il li ia al l   A Ad de en no om ma at to ou us s   P Po ol ly yp po os si is s
Until recently there has been only circumstantial
evidence to suggest that other genetic changes could
give rise to a disease with a phenotype similar to FAP .
Initially, this was demonstrated using linkage analysis
that clearly showed some families displaying that an
atypical  polyposis  phenotype  were  not  linked  to
chromosome 5q21. Very recently a gene associated with
base excision repair can, if mutated in the homozygous
state, result in a phenotype similar to FAP , although the
number of colorectal adenomas does appear to be
slightly less than that expected in FAP associated with
germline mutations in the APC gene. The gene in
question is the MYH gene, located on Chromosome
1p32-34, and it differs from APC and indeed most other
genetic predispositions to colorectal cancer identified to
date  in  that  it  appears  to  be  associated  with  an
autosomal recessive disease inheritance pattern [51-
53]. The recessive inheritance pattern of the disease is
in essence consistent with other familial predispositions
to CRC in that disease development only occurs once
there is a complete loss or change of function. 
M Mo od di if fi ie er r   G Ge en ne es s   t th ha at t   m ma ay y   I In nf fl lu ue en nc ce e   
t th he e   L Li ik ke el li ih ho oo od d   o of f   C Co ol lo or re ec ct ta al l   
C Ca an nc ce er r   D De ev ve el lo op pm me en nt t
Although some phenotypic variation may be due to
differences in mutant alleles of the APC gene there can
be considerable differences in disease presentation even
among family members who carry identical germline
APC mutations. For instance, some family members
may present with only a few colonic polyps whereas
others have thousands and still others may manifest a
variety of other non-gastrointestinal tumors such as
osteomas, sarcomas, and desmoids [15, 54]. Such
variation within families may be due to varying degrees
of  environmental  stress  (such  as  diet),  a  genetic
background (i.e. modifier genes) or both. Unfortunately,
it is difficult to determine what influence environmental
or genetic modifiers have in human pedigrees. Since
the identification of the APC gene and the presence of
a naturally occurring autosomal dominantly transmitted
mouse equivalent of FAP (known as the Multiple
Intestinal  Neoplasia  or  Min mouse)  harboring  a
germline mutation in the mouse Apc gene (written Apc
to designate mouse) questions concerning disease
expression and penetrance could be addressed.
Min mice thus provide a model system for studying
human FAP and in particular for identifying genes that
can modify the phenotype caused by the Apc mutation.
The advantage of using the Min mouse is that it is derived
from an inbred strain of mice (C57BL/6J-Min/+). When
bred pure the average number of tumors in each mouse
is about 29. When Min mice were crossed with another
inbred strain of mouse, AKR, the average number of
tumors dropped to 6 per animal [55]. This finding
suggested that the AKR mouse carries alleles that can act
in a dominant fashion to modify the tumorigenic affect
of Min. Genetic mapping studies identified a locus on
mouse chromosome 4 that strongly modifies tumor
multiplicity  termed  Mom-1 (for  Modifier  of  Min).
Interestingly, Mom-1 lies in a region of synteny with the
human chromosomal segment 1p35-36, a region that
shows frequent somatic loss of heterozygosity in a variety
of human tumor types, including colon [56]. In 1995, a
candidate was identified, the secretory phospholipase A2
gene (sPLA2), which is believed to account for about 50%
of the variation seen in Min mice [57]. In Min mice there
is low sPLA2 activity whereas in AKR mice its activity is
very high. Secretory phospholipase A2 is one of several
enzymes involved in generating arachidonic acid and
lysophosphatidic acid. Arachidonic acid is the rate-limiting
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step in the synthesis of prostaglandins and leukotrienes
[58] and is therefore in low abundance in the C57BL/6J-
Min/+ mouse but its levels are high and hence protective
in the AKR mouse. This evidence creates a dilemma as
there are several studies indicating that non-steroidal anti-
inflammatory drugs (NSAIDs) can decrease the level of
specific prostaglandin E2 in the colonic mucosa [59] by
inhibiting cyclooxygenase. 
Other polymorphic genes exist apart from sPLA2,
which may also alter the likelihood of either disease
development or expression. It is to be expected that any
gene that is capable of affecting disease is likely to be
represented within the population in several different
forms at relatively high frequency, such examples include
N-acetyl transferase and glutathione-S-transferase. 
P Pr re ev ve en nt ti io on n   a an nd d   T Th he er ra ap py y   o of f   F FA AP P
Disease prevention in persons suffering from FAP has
and will continue to be prophylactic removal of the colon
before progression occurs. An often quoted age for this
operative procedure is twenty years of age. Recently, it
has become recognised that certain non-steroidal anti-
inflammatory drugs (NSAIDs) such as Sulindac (Clinoril)
and aspirin may be beneficial in reducing polyp size and
number [59] and that there may even be site specific
affects [7]. The action of NSAIDs and aspirin is believed
to work by inhibiting the enzyme cyclo oxygenase, which
in  turn  leads  to  a  decrease  in  the  formation  of
prostaglandins. Decreasing the levels of prostaglandins
appears to have a protective effect with respect to colonic
disease development. The exact mechanism by which
NSAIDs operate is, however, unknown as there appears
to be more to it than merely inhibition of arachidonic acid
synthesis and hence prostaglandins formation. In addition,
there is reason to believe that dietary resistant starch may
also lead to a reduction of polyp number and size [60].
It must be stressed, however, that NSAIDs are no substitute
for total colectomy in FAP . There are reports of cancer
development in patients taking NSAIDs even when
significant polyp regression had occurred [61].
S Sy yn nd dr ro om me es s   w wi it th h   P Pr re ee ex xi is st ti in ng g   
h ha am ma ar rt to om ma at to ou us s   P Po ol ly yp ps s
P Pe eu ut tz z- -J Je eg gh he er rs s  s sy yn nd dr ro om me e
Peutz-Jeghers syndrome is an autosomal dominantly
inherited condition affecting both sexes equally, which
predisposes to the development of gastrointestinal
adenocarcinoma. Penetrance is incomplete and often
the genetic defect develops as a result of a spontaneous
mutation  [62].  A  unique  type  of  gastrointestinal
hamartoma, mucocutaneous pigmentation, as well as
extra-gastrointestinal  neoplasms  characterizes  the
disease. A typical feature of Peutz-Jeghers hamartomas
is a smooth muscle core derived from the muscularis
mucosae and extending into the polyp. The mucosa
covering the polyp is similar to that found in the region
of the gut in which it occurs [62, 63]. A second feature,
which is one of the most significant characteristics of
the  disease,  is  the  presence  of  mucocutaneous
pigmentation. Pigmented macules occur most often on
the lips and buccal mucosa and less commonly on the
eyelids and dorsal surfaces of fingers and soles of the
feet. The presence of these symptoms is not usually
detected at birth but appears after the first or second
year of life. As the patients age the lip pigmentation
fades whereas buccal pigmentation does not.
Sufficient evidence exists in the literature to indicate
clearly that patients with Peutz-Jeghers syndrome are at
increased risk of developing adenocarcinoma of the
gastrointestinal tract. The majority of these lesions are
located in the stomach, duodenum, and colon. The
prevalence of GI carcinoma is not accurately known
but it is estimated to be between 2% and 20%. Debate
remains as to whether carcinoma in this syndrome arises
from  either  malignant  transformation  of  a
hamartomatous polyp, coexisting adenoma or de novo
[64-66]. In addition to GI tract tumors, extra-intestinal
tumors are also observed in patients with this syndrome.
The prevalence of extra-intestinal tumors varies from
between 10% and 30% with the most commonly
reported  tumors  being  pancreas,  breast  and
reproductive  organs  [67-70].  The  incidence  of
pancreatic cancer is about 100 times that expected
and occurs at unusually early ages [67, 69, 70-73].
An  increased  frequency  of  breast  cancer  is  also
observed and is usually bilateral and ductal in origin
[68, 70, 74-76]. Neoplasms of the reproductive tract
such as adenoma malignum (a uterine cancer) have
also been reported in Peutz-Jegher’s patients. Benign
microscopic ovarian tumors designated ovarian sex cord
tumors with annular tubules are also considered to be
present in most women with this syndrome [77-81]. The
genetic locus for PJS was identified in 1996 and found
to lie on chromosome 19p13.3, however, not all
families typed were linked to this locus and a second
site was identified at position 19q13.4 [82]. A putative
gene was identified which mapped to the Ch 19p13.1
region, termed initially LKB1, which was homologous
to the serine threonine kinase STK11 [83, 84]. Since
the identification of STK11 several studies have shown
that germline mutations in this gene appear to account
for up to half of all families [85, 86].H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2003; 1(1) 26
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(macrocephaly, pigmented macules on the penis)
This rare syndrome originally included a small
group of patients with features of macrocephaly,
pigmented genital lesions, intestinal polyposis and an
autosomal dominant inheritance pattern [87, 88].
Intestinal hamartomatous polyposis is seen in 45% of
patients and appears to be limited to the distal part of
the colon. Additional features of the disease include
subcutaneous visceral lipomas and hemangiomas [89].
No defined genetic locus has been described.
J Ju uv ve en ni il le e  p po ol ly yp po os si is s  
Genetically, juvenile polyposis is not precisely
defined. Approximately 25% of cases are transmitted
as an autosomal dominant trait [90-95]. Juvenile polyps
are usually pedunculated hamartomas and can be seen
in both children and adults. The hamartomas may
ulcerate, bleed or cause obstruction, with time they tend
to self amputate. Patients with juvenile polyposis are at
increased risk of developing malignant intestinal tumors
(especially colorectal cancer), most often diagnosed in
the 2nd or 3rd decade [96-103]. Precancerous lesions
have been well documented within juvenile polyps
suggesting that carcinomas arise out of these lesions
[63]. In addition to colorectal lesions, carcinoma of the
stomach, duodenum and pancreas has also been
reported in juvenile polyposis patients. Epidemiological
evidence suggests that family members of juvenile
polyposis  patients  are  also  at  increased  risk  of
developing gastrointestinal malignancies. Recently the
SMAD4 (or DPC) gene has been implicated in the
development of this syndrome. The function of SMAD4
is  associated  with  the  mediation  of  signals  from
transforming growth factor (TGF) beta and related
ligands such that SMAD4 mediates TGF-beta-stimulated
gene transcription [104].
C Co ow wd de en n’ ’s s  D Di is se ea as se e
This  multiple  hamartomata  syndrome  is  a
genodermatosis characterized by hamartomas and
neoplasms of ectodermal, mesodermal and endodermal
origin affecting multiple organs and organ systems [105,
106]. To date around 160 cases have been reported in
the literature. The syndrome is an autosomal dominantly
inherited disease and occurs primarily in Caucasians.
Mucocutaneous lesions are present in all patients and
are considered a hallmark of the disease. Facial papules,
oral mucosal papilomatoses, acral keratoses and
multiple sclerotic fibromas appear to be the most
characteristic features of the disease [106-111]. The
majority of cases are diagnosed between the ages of
30 and 40 years. The most consistent clinical features
are mucocutaneous lesions associated with a variety of
thyroid gland abnormalities, breast carcinoma and
hamartomatous polyposis of the gastrointestinal tract
[106-108, 112].
Hamartomatous polyps of the gastrointestinal tract
occur  in  approximately  40-70%  of  patients  with
Cowden’s disease. Histopathologically, the appearance
of gastrointestinal polyps is difficult to classify as a wide
variety of findings have been reported [109, 113-117].
The  majority,  however,  are  now  recognised  as
hamartomas [63, 106, 107, 112, 113]. The multiple
hamartoma syndrome (MHS) hamartomas differ from
the Peutz-Jeghers hamartoma by several distinctive
features. The MHS hamartoma is usually sessile,
smaller  and  have  less  exophytic  and  arborizing
proliferation of the muscularis mucosae [63, 113].
Thyroid  abnormalities  are  the  most  frequent
extracutaneous abnormality, occurring in approximately
65% of patients. Goitres and adenomas are the most
common lesions and affect equally men and women
[106, 108]. Thyroid follicular adenocarcinoma has also
been reported in 3-12% of patients, all of which have
been found in women [106, 107]. Recently, a genetic
locus for Cowden’s disease has been identified on
chromosome 10q22–23 by a genomic wide screening
strategy and loss of heterozygosity analysis of tumors
that comprise part of the spectrum of the disease [118].
The  PTEN  gene  is  a  putative  protein  tyrosine
phosphatase [119] that is essential for embryonic
development and tumor suppression [120]. Several
patients with Cowden’s disease have now been shown
to harbor germline mutations in the PTEN gene [121]
thus  providing  strong  evidence  for  it  being  the
predisposing genetic factor involved in the transmission
of this disease from generation to generation. 
C Co on nc cl lu us si io on n
It is widely accepted that colorectal cancer develops
as a result of a progressive series of genetic alterations
in oncogenes and tumor suppresser genes. In an
inherited predisposition such as FAP , it is the germline
mutation  of  the  APC  gene  that  initiates  disease
development  and  any  genetic  events  occurring
thereafter are associated with disease progression. In
addition, the genetic background of the affected
persons plays a major role in disease presentation. It
is  only  now  becoming  apparent  that  familial
predispositions to colorectal cancer preceded by either
hamartomatous or adenomatous polyposis are best
described as monogenetic diseases but are influenced
by diverse genetic and environmental factors. With
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increased knowledge of the molecular mechanisms
underlying the development of inherited predispositions
to colorectal cancer will better and more targeted
therapies and prevention strategies be developed.
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